Use of SGLT2 inhibitors was associated with lower 5-year risk for chronic kidney disease and AKI compared with GLP-1 receptor ...

Danish national registry data suggest adults with type 2 diabetes taking SGLT2 inhibitors have a slightly lower risk of developing diabetic foot problems than those taking GLP-1 receptor agonists.

SGLT2is showed a lower 5-year risk of CKD and fewer AKI events compared to GLP-1 RAs in type 2 diabetes patients. The study utilized Danish registry data, including 55,061 participants, with balanced ...

A new study published in the Journal of American Medical Association showed that when renal protection is a primary therapeutic objective, starting treatment with an SGLT2 inhibitor (SGLT2i) ...

Patients with type 2 diabetes and inflammatory arthritis who received GLP-1 RAs had lower rates of hypoglycemia, serious infections, and acute kidney injury vs those receiving SGLT2 inhibitors.

—Study findings highlight the need for improved recommendations of guideline-directed therapies and support the consideration of dual therapy in appropriately selected high-risk patients. In a study ...

Nearly 60% of US adults qualify for at least one novel cardiovascular, kidney, or metabolic drug — most often a GLP-1 receptor agonist — with many eligible for more than one class of drugs.

The registry cohort included 53,769 and 30,380 new users of SGLT-2is and GLP-1 RAs, respectively. HealthDay News — For adults with type 2 diabetes mellitus (T2DM), new users of sodium-glucose ...

A large cohort study found three popular GLP-1-based diabetes drugs -- semaglutide, dulaglutide, and tirzepatide -- carry similar risks for serious adverse GI events, with a rate of about 12 per 1,000 ...

With more studies emerging, GLP-1 and dual GIP/GLP-1 medications have become well-established options for those with obesity or type 2 diabetes. These treatments can positively affect appetite, ...